...
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Design of PEG-grafted-PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model Famotidine
【24h】

Design of PEG-grafted-PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model Famotidine

机译:P-GP底物药物模型Famotidine设计PEG-接枝 - PLA纳米粒子作为口服渗透性增强剂的设计

获取原文
获取原文并翻译 | 示例
           

摘要

Bioavailability of oral drugs can be limited by an intestinal excretion process mediated by P-glycoprotein (P-gp). Polyethylene glycol (PEG) is a known P-gp inhibitor. Dispersion of Famotidine (a P-gp substrate) within PEGylated nanoparticles (NPs) was used to improve its oral bioavailability. In this work, we evaluated the potential impact of NPs prepared from a grafted copolymer of polylactic acid and PEG on P-gp function by studying in vitro permeability of Famotidine across Caco-2 cells. Copolymers of PEG grafted on polylactic acid (PLA) backbone (PLA-g-PEG) were synthesised with 1mol% and 5mol% PEG vs. lactic acid monomer using PEG 750 and 2000Da. The polymers were used to prepare Famotidine-loaded NPs and tested in vitro on Caco-2 cells. Significant decrease in basolateral-to-apical transport of Famotidine was observed when Famotidine was encapsulated in NPs prepared from PLA-g-PEG5%. NPs prepared from PLA-g-PEG5% are promising to improve oral bioavailability of P-gp substrates.
机译:口腔药物的生物利用度可以受到p-糖蛋白(P-GP)介导的肠道排泄过程的限制。 聚乙二醇(PEG)是已知的P-GP抑制剂。 Facotidine(P-GP衬底)在聚乙二醇化纳米颗粒(NPS)中的分散用于改善其口腔生物利用度。 在这项工作中,我们通过在CaCO-2细胞上研究Facotidine的体外渗透性,评估了NPS从P-GP功能的接枝共聚物的潜在影响。 使用PEG 750和2000DA用1mol%和5mol%PEG与乳酸单体合成嫁接在聚乳酸(PLA)主链(PLA-G-PEG)上的共聚物。 聚合物用于制备富含氟辛胺的NP,并在CaCO-2细胞上进行体外测试。 当Famotidine包封在由PLA-G-PEG5%制备的NPS中包封时,观察到Famotidine的基底外侧到顶端传输的显着降低。 从PLA-G-PEG5%制备的NPS很有希望提高P-GP基材的口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号